NorthWest Biotherapeutics Inc (NWBO)

[JSwy17]

OR, what technology they may want to partner with, OR BUY that is BETTER than this;

2 immediate deaths out of 16 patients treated means Juno needs to back off their potency (or dose level), find immune response controls, and/or restrict it to patients that can tolerate the treatment.

I hope they can get past "several" worrisome side effect issues. Particularly Runaway cytokine release syndrome in such a high percentage of patients. Next, they will need to get the cost down from $500,000.00 per patient -- if Citibank's estimate is correct.

Finally, it will be interesting what response they achieve in solid tumor applications. flipper44